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C

omplicated urinary tract infections (cUTI) are a leading cause of hospitalization due
to infections in the United States (1, 2). Increasing rates of antimicrobial resistance
have limited the options for oral empirical therapy of cUTI (3–5). The rates of resistance
to ﬂuoroquinolones (FQ), trimethoprim-sulfamethoxazole, and amoxicillin-clavulanate
among Escherichia coli isolates have exceeded 20% in multiple geographical settings in
North America (6–8). Despite increasing rates of antimicrobial resistance, ﬂuoroquinolones remain among the antimicrobial agents most commonly prescribed for the
treatment of cUTI (9).
The ﬂuoroquinolone resistance score (FQRS) was recently developed by our group
to predict the probability of ﬂuoroquinolone resistance in bloodstream Gram-negative
isolates. The score is based on male sex (1 point), diabetes mellitus (1 point), residence
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ABSTRACT The ﬂuoroquinolone resistance score (FQRS) predicts the probability of
ﬂuoroquinolone resistance with good discrimination. The score has been derived
from patients with bloodstream infections caused by Gram-negative bacteria and is
based on ﬂuoroquinolone use within the past 6 months, among other clinical and
health care exposure criteria. This study aims to examine the utility of the FQRS in
patients with complicated urinary tract infections (cUTI) and determine whether extension of prior ﬂuoroquinolone use to 12 months improves model discrimination.
Adults with cUTI at Palmetto Health in central South Carolina, USA, from 1 April
2015 through 31 July 2015 were prospectively identiﬁed. Multivariate logistic regression was used to examine the association between prior ﬂuoroquinolone use and resistance. Among 238 patients, 54 (23%) had cUTI due to ﬂuoroquinolone-resistant
bacteria. Overall, the median age was 66 years, 162 (68%) patients were women, and
137 (58%) patients had cUTI due to Escherichia coli. Prior exposure to ﬂuoroquinolones within 3 months (adjusted odds ratio [aOR], 23.4; 95% conﬁdence interval [CI],
8.2 to 76.8; P ⬍ 0.001) and within 3 to 12 months (aOR, 13.2; 95% CI, 3.1 to 68.4;
P ⬍ 0.001) was independently associated with ﬂuoroquinolone resistance compared
to no prior use. The area under the receiver operating characteristic curve for the
FQRS increased from 0.73 to 0.80 when prior ﬂuoroquinolone use was extended
from 6 to 12 months. FQRSs of ⱖ2 and ⱖ3 had negative predictive values of 91%
and 90%, respectively. The modiﬁed FQRS stratiﬁes patients with cUTI on the basis
of the predicted probability of ﬂuoroquinolone resistance with very good discrimination. Application of the modiﬁed FQRS may improve antimicrobial utilization in patients with acute pyelonephritis.
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TABLE 1 Demographics and clinical characteristics of patients with cUTI and risk factors for ﬂuoroquinolone resistance in univariate
modela
Value for patients infected with:
Variable
Median (IQR) age (yr)
No. (%) of male subjects
No. (%) of subjects of white race
No. (%) of subjects with:
Diabetes mellitus
Cancer
Hospital-acquired infection
Recent hospitalizationc
Residence at a skilled nursing facility
Recent outpatient procedured
Prior ﬂuoroquinolone use
None
Within 3 mo
Within 3–12 mo

FQ-NS bacteria
(n ⴝ 54)
69 (59–81)
21 (39)
29 (53)

FQ-S bacteria
(n ⴝ 184)
65 (54–76)
55 (30)
83 (45)

OR
1.18b
1.49
1.41

95% CI
0.98–1.43
0.79–2.94
0.77–2.61

P value
0.09
0.22
0.27

21 (39)
13 (24)
9 (17)
25 (46)
10 (19)
6 (11)

71 (39)
33 (18)
38 (21)
61 (33)
18 (10)
5 (3)

1.01
1.45
0.77
1.74
2.10
4.48

0.54–1.88
0.68–2.96
0.33–1.65
0.93–3.22
0.88–4.79
1.30–16.13

0.97
0.32
0.51
0.08
0.09
0.02

21 (39)
18 (33)
15 (28)

171 (93)
6 (3)
7 (4)

1
24.43
17.45

Referent
9.18–73.91
6.60–50.47

Referent
⬍0.001
⬍0.001

acUTI,

complicated urinary tract infections; OR, odds ratio; CI, conﬁdence interval; IQR, interquartile range.
decade.
cWithin 3 months of infection.
dWithin 1 month of infection.

at a skilled nursing facility (2 points), recent outpatient procedures (3 points), and prior
ﬂuoroquinolone use (within 3 months, 5 points; within 3 to 6 months, 3 points). The
FQRS stratiﬁes patients with bloodstream infections caused by Gram-negative bacteria
according to the predicted risk of ﬂuoroquinolone resistance with good discrimination
on the basis of an area under a receiver operating characteristic curve (AUC) of 0.73
(10).
The aim of this study was to prospectively examine the utility of the FQRS in the
management of patients with cUTI and examine whether extension of ﬂuoroquinolone
use up to 12 months prior to infection improves model discrimination.
(The preliminary results of this study were presented, in part, at IDWeek, 26 to 30
October 2016, New Orleans, LA, USA [11].)
RESULTS
During the 4-month study period, 238 patients with cUTI were included. Overall, the
median age was 66 years, and 76 (32%) of the patients were men. Escherichia coli was
the most common pathogen (n ⫽ 137 patients; 58%), followed by Klebsiella pneumoniae (n ⫽ 37; 16%), Pseudomonas aeruginosa (n ⫽ 14; 6%), Enterobacter cloacae (n ⫽
13; 5%), Proteus mirabilis (n ⫽ 10; 4%), Serratia marcescens (n ⫽ 10; 4%), Enterobacter
aerogenes (n ⫽ 7; 3%), and others (n ⫽ 10; 4%). Among the patients in this cohort, 54
(23%) had cUTI due to ﬂuoroquinolone-nonsusceptible (FQ-NS) Gram-negative bacilli.
The baseline demographics and clinical characteristics of the patients with cUTI due to
FQ-NS and ﬂuoroquinolone-susceptible (FQ-S) bacteria are shown in Table 1.
Univariate logistic regression results for risk factors for infection with FQ-NS bacteria are
demonstrated in Table 1. In the multivariate model, male sex, residence at a skilled
nursing facility, outpatient procedures within 1 month of the index infection, and prior
ﬂuoroquinolone use within 3 months and within 3 to 12 months of the index infection
were independently associated with ﬂuoroquinolone resistance (Table 2).
On the basis of multivariate logistic regression results, the FQRS was modiﬁed by
extending prior ﬂuoroquinolone exposure from 6 to 12 months (Table 3). The AUC for
the FQRS model increased from 0.73 to 0.80 when prior ﬂuoroquinolone use was
extended from 6 months (not shown) to 12 months (Fig. 1). The performance characteristics of the modiﬁed FQRS as a binary classiﬁcation test are demonstrated in Table
4. The negative predictive values (NPVs) were 94%, 91%, and 90% when FQRS cutoff
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TABLE 2 Independent risk factors for ﬂuoroquinolone resistance in multivariate logistic
regression modela
Variable
Male sex
Diabetes mellitus
Residence at a skilled nursing facility
Outpatient GI/GU procedure within 1 mo

aOR
2.22
1.48
2.80
6.65

95% CI
1.00–5.34
0.71–3.14
1.02–7.25
1.47–29.78

P value
0.049
0.29
0.046
0.01

Prior ﬂuoroquinolone use within 12 mo
None
Within 3 mo
Within 3–12 mo

1
23.35
13.16

Referent
8.20–76.85
3.11–68.43

Referent
⬍0.001
⬍0.001

aaOR,

adjusted odds ratio; CI, conﬁdence intervals; GI, gastrointestinal; GU, genitourinary.

DISCUSSION
This study supports the use of the FQRS for the management of patients with cUTI.
On the basis of prior and current results, the FQRS predicts the risk of ﬂuoroquinolone
resistance with good discrimination both in patients with bloodstream infections
caused by Gram-negative bacteria and in patients with cUTI, respectively (AUC ⫽ 0.73
for both) (10). Modiﬁcation of the FQRS by extension of ﬂuoroquinolone use up to 12
months prior to infection improves the discriminative ability of the model (AUC ⫽ 0.80).
It is alarming that ﬂuoroquinolone use in patients with cUTI predisposes these
patients to an increased risk of ﬂuoroquinolone resistance up to 1 year after exposure.
This is supported by the results of a recent study which demonstrated the persistent
impact of antimicrobials on the intestinal ﬂora up to 1 year after exposure (12). This
highlights the signiﬁcance of antimicrobial stewardship efforts to reduce the unnecessary use of ﬂuoroquinolones for the treatment of mild infections, e.g., upper respiratory
tract infections and uncomplicated cystitis. The risks of ﬂuoroquinolone therapy, including the induction of antimicrobial resistance, in patients with these minor infections exceed the potential beneﬁts (13). Fluoroquinolones are potentially life-saving
antimicrobial agents. Due to recent safety concerns and updates to ﬂuoroquinolone
labels by the U.S. Food and Drug Administration, ﬂuoroquinolone use should be
reserved for patients with potentially life-threatening infections (13). Narrowerspectrum antimicrobial agents are more appropriate for less serious infections. Fluoroquinolone therapy is not appropriate in patients with uncomplicated cystitis when
other treatment options (e.g., nitrofurantoin, fosfomycin, and trimethoprim-sulfamethoxazole) are available (2, 14).

TABLE 3 Modiﬁed FQRSa
Risk factor for ﬂuoroquinolone resistance
Male sex
Diabetes mellitus
Residence in a skilled nursing facility
Outpatient GI/GU procedure within past 1 mo

Point allocation
1
1
2
3

Prior ﬂuoroquinolone use within past 12 mo
None
Within 3 mo
Within 3–12 mo

0
5
3

aFQRS,

ﬂuoroquinolone resistance score; GI, gastrointestinal; GU, genitourinary.
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points of ⱖ1, ⱖ2, and ⱖ3 were used to indicate a high risk of ﬂuoroquinolone
resistance.
The risk of ﬂuoroquinolone resistance in patients with cUTI predicted using the
modiﬁed FQRS is shown in Fig. 2. Patients with FQRSs of 0 and 1 have relatively low
predicted probabilities of ﬂuoroquinolone resistance of 6% and 10%, respectively. The
estimated risk of ﬂuoroquinolone resistance increases to 31% in patients with an FQRS
of 3 and to 60% in patients with an FQRS of 5.
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In the era of increasing antimicrobial resistance, creative solutions to maintain the
adequacy of antimicrobial therapy in patients with serious infections by optimizing the
utilization of currently available resources are of paramount importance. Fluoroquinolones are among the most effective oral antimicrobial agents for the treatment of acute
pyelonephritis due to their excellent oral bioavailability and high urinary and tissue
concentrations (15). However, increasing rates of ﬂuoroquinolone resistance have
complicated the management of acute pyelonephritis, particularly in outpatient settings. The current national guidelines recommend using oral ﬂuoroquinolones in
patients with acute pyelonephritis not requiring hospitalization in settings with a ⬍10%
overall prevalence of ﬂuoroquinolone resistance among uropathogens (2). However,
geographical locations with a ⬍10% overall prevalence of resistance to ﬂuoroquinolones hardly exist these days in North America or elsewhere (3–8). This forces the
administration of intravenous ceftriaxone to most patients with acute pyelonephritis
prior to discharge from the emergency room or other outpatient settings on oral
ﬂuoroquinolones (2). The FQRS presents health care providers with opportunities to
improve antimicrobial utilization in acute pyelonephritis by categorizing patients
on the basis of the predicted probability of ﬂuoroquinolone resistance into 3
groups: low, moderate, and high risk (Fig. 3). These categories are based on the
performance characteristics of the modiﬁed FQRS using cutoff points of ⱖ2 and ⱖ3
to optimize the NPV and positive predictive value (PPV), respectively. Patients with
an FQRS of 0 and 1 have a 6% and 10% predicted probability of ﬂuoroquinolone
resistance, respectively (Fig. 2), corresponding to a NPV of 91% for an FQRS of ⱖ2.
Since the predicted rate of resistance to ﬂuoroquinolones is ⬍10% in this low-risk
group, patients with an FQRS of ⬍2 are eligible for empirical oral ﬂuoroquinolone
therapy without the need for administration of intravenous ceftriaxone, in concordance with the national management guidelines (2). Application of the FQRS may
simplify antimicrobial management in the majority of patients with acute pyelone-

TABLE 4 Performance of modiﬁed FQRS as a binary classiﬁcation testa
FQRS cutoff point
ⱖ1
ⱖ2
ⱖ3b

Sensitivity (%)
93
76
69

Speciﬁcity (%)
33
68
84

PPV (%)
29
41
56

NPV (%)
94
91
90

aFQRS,

ﬂuoroquinolone resistance score; PPV, positive predictive value; NPV, negative predictive value.
use of a cutoff score of ⱖ3 to indicate a high predicted risk of ﬂuoroquinolone resistance provides the
best performance in the statistical model.

bThe
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FIG 1 Receiver operating characteristic plot of the modiﬁed ﬂuoroquinolone resistance score. The black
line indicates the receiver operating characteristic curve. The light color tangent line highlights the point
in the curve that represents the best performance of the model. The area under the curve was 0.80.
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phritis, since 60% of patients in the current study met the criteria for the low-risk
category (no prior ﬂuoroquinolone use, outpatient procedures, or residence at a
skilled nursing facility). The management of patients in the moderate-risk group
(FQRS ⫽ 2) remains unchanged from current guidelines since the predicted probability of ﬂuoroquinolone resistance in this group is comparable to the overall
resistance rate in the study (19% and 23%, respectively). The FQRS also identiﬁes
patients in whom ﬂuoroquinolone therapy is most likely inadequate. If ﬂuoroquinolones were initially prescribed to patients with acute pyelonephritis in the high-risk
category, the majority would undergo revision of antimicrobial therapy when in
vitro antimicrobial susceptibility testing results become available, given a PPV of
56% for an FQRS of ⱖ3. Unfortunately, current data are insufﬁcient to recommend
alternative oral antimicrobial agents in this group. It would be valuable to develop
clinical scores to predict resistance to other oral antimicrobial agents with a high
efﬁcacy in the treatment of cUTI, e.g., trimethoprim-sulfamethoxazole, in future
studies. That would help identify other potential oral options for patients with a
high risk of ﬂuoroquinolone resistance and may diversify antimicrobial prescriptions
overall.
In the inpatient setting, utilization of the FQRS may allow the early discharge of
hospitalized patients with cUTI who demonstrate clinical improvement prior to the
availability of urine culture and in vitro antimicrobial susceptibility testing results. If
used properly, this may confer signiﬁcant cost savings for the health care system.
However, the FQRS should not replace in vitro antimicrobial susceptibility testing.

FIG 3 Proposed algorithm for application of the modiﬁed FQRS in the outpatient management of acute
pyelonephritis. FQRS, ﬂuoroquinolone resistance score; IV, intravenous.
May 2017 Volume 61 Issue 5 e02313-16
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FIG 2 Predicted probability of ﬂuoroquinolone resistance by modiﬁed ﬂuoroquinolone resistance score.
The size of the marker for point estimates is weighted approximately by the relative number of subjects
with the corresponding score.
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Antimicrobial therapy should be adjusted, if needed, on the basis of organism identiﬁcation and in vitro antimicrobial susceptibility testing results.
In addition to its clinical applications, the FQRS may also be used in clinical research
studies. Increasing rates of ﬂuoroquinolone resistance limited the utility of ﬂuoroquinolones as comparators to a new antimicrobial agent for cUTI in a recent clinical trial (16).
Exclusion of patients with a high predicted risk of ﬂuoroquinolone resistance, such as
those with an FQRS of ⱖ3, would make comparisons between ﬂuoroquinolones and
new antimicrobial agents more meaningful.
This study has strengths and limitations. The identiﬁcation of cases and risk factors
for antimicrobial resistance was facilitated by having a centralized microbiology laboratory and access to both inpatient and outpatient records from several afﬁliated
medical facilities in the region. The patients’ prior antimicrobial treatment histories
were available, for the most part, in electronic medical records, including medication
administration records and electronic prescriptions. Utilization of the FRQS in settings
that lack access to prior records would heavily depend on patients’ recall of their prior
use of antimicrobial agents and providers’ efforts to ascertain medical records. In
addition, the case-control section of the current study was not powered to demonstrate
an association between ﬂuoroquinolone resistance and each individual component of
the FQRS. Rather, it was focused on examining the risk of ﬂuoroquinolone resistance on
the basis of ﬂuoroquinolone exposure within the past 12 months. Four of the variables
in the FQRS were identiﬁed as independent risk factors for ﬂuoroquinolone resistance
in the current study. The role of diabetes mellitus in predicting ﬂuoroquinolone
resistance remains unclear on the basis of the current results. Moreover, although the
impact of gender on antimicrobial resistance was statistically signiﬁcant, it warrants
further explanations in populations with different antimicrobial consumption and
dietary habits.
In summary, the modiﬁed FQRS stratiﬁes patients with cUTI on the basis of the
predicted probability of ﬂuoroquinolone resistance with very good discrimination.
Application of the modiﬁed FQRS may simplify antimicrobial management in patients
with acute pyelonephritis and improve the design of future clinical trials.
MATERIALS AND METHODS
Setting. The study was conducted at Palmetto Health inpatient and outpatient facilities in central
South Carolina, USA. These facilities included three large community hospitals with a combined capacity
of nearly 1,200 licensed beds, three emergency rooms, several afﬁliated urgent treatment centers, and
ambulatory care clinics. The Institutional Review Board at Palmetto Health approved the study.
Deﬁnitions. Patients were considered to have cUTI if they had urinary symptoms or signs and
monomicrobial growth of Gram-negative bacilli in urine cultures in the presence of complications
such as obstructive uropathy, indwelling urinary catheters, urinary retention from neurologic
disease, or bladder outlet obstruction (17, 18). Patients with clinical manifestations of acute
pyelonephritis (temperature of ⬎38°C, unilateral ﬂank pain, or costovertebral angle tenderness) and
monomicrobial growth of Gram-negative bacilli in urine cultures were also included among those
with cUTI (19). Outpatient procedures included both invasive procedures (e.g., bladder, colon, and
prostate biopsies) and noninvasive procedures (e.g., colonoscopy, cystoscopy, and duodenoscopy)
(10). Fluoroquinolone-nonsusceptible (FQ-NS) isolates were deﬁned as Gram-negative bacilli that
had intermediate in vitro susceptibility to ciproﬂoxacin (MIC ⫽ 2 g/ml) or were resistant in vitro to
ciproﬂoxacin (MIC ⱖ 4 g/ml) according to Clinical and Laboratory Standards Institute guidelines.
Case ascertainment. All adult patients ⱖ18 years old with growth of Gram-negative bacilli in urine
cultures from 1 April 2015 to 31 July 2015 were prospectively identiﬁed through a real-time alert system
which interfaced with the central microbiology laboratory at Palmetto Health (n ⫽ 582). Patients with
polymicrobial growth of bacteria in urine cultures (n ⫽ 56) or recurrent episodes of positive urine cultures
during the study period (n ⫽ 11) and those with positive urine cultures who did not meet the predeﬁned
criteria for cUTI (n ⫽ 277) were excluded. Patients with recurrences and polymicrobial growth of bacteria
in urine cultures were excluded to avoid enrolling the same patient as a case and a control. A total of
238 unique adults with cUTI were included in the study. Demographic, microbiology, and clinical data,
including potential risk factors for antimicrobial resistance, were collected from electronic medical
records. The receipt of ﬂuoroquinolones in the 12 months preceding the cUTI was ascertained from
medication administration records, electronic prescriptions, and clinical notes from current and prior
hospitalizations and visits to afﬁliated emergency rooms or other ambulatory care settings.
Statistical analysis. Logistic regression was used to examine the association between ﬂuoroquinolone resistance and ﬂuoroquinolone exposure up to 12 months prior to the index cUTI in a
case-control design. For the simpliﬁcation of statistical analysis, Gram-negative bacilli that were
May 2017 Volume 61 Issue 5 e02313-16
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